Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
Patients undergoing hip fracture repair are at significant risk for deep vein thrombosis and pulmonary embolism in the postoperative period without appropriate prophylaxis. Agents available in the United States that have undergone clinical trials as pharmacoprophylaxis for this indication include warfarin, dalteparin, and danaparoid. Safety and efficacy data from these trials were used to determine the most cost-effective agent for routine deep vein thrombosis prophylaxis in patients with hip fractures. Incremental cost-effectiveness ratio calculations demonstrate that warfarin dosed to an international normalized ratio of 2-2.7 is currently the most cost-effective agent in these patients.
Wade
W E
WE
College of Pharmacy, University of Georgia, Athens, USA.
Chisholm
M A
MA
D000925:Anticoagulants / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017985:Dalteparin / Q000191:economics / Q000627:therapeutic use; D006620:Hip Fractures / Q000601:surgery*; D006801:Humans; D007866:Leg / Q000098:blood supply; D011183:Postoperative Complications / Q000191:economics / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics* / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D017985:Dalteparin